Optimal Dosing and Dynamic Distribution of Vaccines in an Influenza Pandemic
Identifieur interne : 000874 ( Ncbi/Merge ); précédent : 000873; suivant : 000875Optimal Dosing and Dynamic Distribution of Vaccines in an Influenza Pandemic
Auteurs : James Wood ; James Mccaw ; Niels Becker ; Terry Nolan ; C. Raina MacintyreSource :
- American Journal of Epidemiology [ 0002-9262 ] ; 2009.
Descripteurs français
- KwdFr :
- MESH :
- administration et posologie : Vaccins antigrippaux.
- épidémiologie : Grippe humaine, États-Unis d'Amérique.
- Facteurs temps, Flambées de maladies, Grippe humaine, Humains, Immunisation, Modèles statistiques, Modèles théoriques, Relation dose-réponse (immunologie).
- Wicri :
- geographic : États-Unis.
English descriptors
- KwdEn :
- Disease Outbreaks (prevention & control), Dose-Response Relationship, Immunologic, Humans, Immunization (statistics & numerical data), Influenza Vaccines (administration & dosage), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Models, Statistical, Models, Theoretical, Time Factors, United States (epidemiology).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- geographic , epidemiology : United States.
- epidemiology : Influenza, Human.
- prevention & control : Disease Outbreaks, Influenza, Human.
- statistics & numerical data : Immunization.
- Dose-Response Relationship, Immunologic, Humans, Models, Statistical, Models, Theoretical, Time Factors.
Abstract
Limited production capacity and delays inherent in vaccine development are major hurdles to the widespread use of vaccines to mitigate the effects of a new influenza pandemic. Antigen-sparing vaccines have the most potential to increase population coverage but may be less efficacious. The authors explored this trade-off by applying simple models of influenza transmission and dose response to recent clinical trial data. In this paper, these data are used to illustrate an approach to comparing vaccines on the basis of antigen supply and inferred efficacy. The effects of delays in matched vaccine availability and seroconversion on epidemic size during pandemic phase 6 were also studied. The authors infer from trial data that population benefits stem from the use of low-antigen vaccines. Delayed availability of a matched vaccine could be partially alleviated by using a 1-dose vaccination program with increased coverage and reduced time to full protection. Although less immunogenic, an overall attack rate of up to 6% lower than a 2-dose program could be achieved. However, if prevalence at vaccination is above 1%, effectiveness is much reduced, emphasizing the need for other control measures.
Url:
DOI: 10.1093/aje/kwp072
PubMed: 19395691
PubMed Central: 2691801
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000572
- to stream Pmc, to step Curation: 000572
- to stream Pmc, to step Checkpoint: 000B77
- to stream PubMed, to step Corpus: 001766
- to stream PubMed, to step Curation: 001766
- to stream PubMed, to step Checkpoint: 001534
Links to Exploration step
PMC:2691801Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Optimal Dosing and Dynamic Distribution of Vaccines in an Influenza Pandemic</title><author><name sortKey="Wood, James" sort="Wood, James" uniqKey="Wood J" first="James" last="Wood">James Wood</name></author><author><name sortKey="Mccaw, James" sort="Mccaw, James" uniqKey="Mccaw J" first="James" last="Mccaw">James Mccaw</name></author><author><name sortKey="Becker, Niels" sort="Becker, Niels" uniqKey="Becker N" first="Niels" last="Becker">Niels Becker</name></author><author><name sortKey="Nolan, Terry" sort="Nolan, Terry" uniqKey="Nolan T" first="Terry" last="Nolan">Terry Nolan</name></author><author><name sortKey="Macintyre, C Raina" sort="Macintyre, C Raina" uniqKey="Macintyre C" first="C. Raina" last="Macintyre">C. Raina Macintyre</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">19395691</idno><idno type="pmc">2691801</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2691801</idno><idno type="RBID">PMC:2691801</idno><idno type="doi">10.1093/aje/kwp072</idno><date when="2009">2009</date><idno type="wicri:Area/Pmc/Corpus">000572</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000572</idno><idno type="wicri:Area/Pmc/Curation">000572</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000572</idno><idno type="wicri:Area/Pmc/Checkpoint">000B77</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000B77</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:19395691</idno><idno type="wicri:Area/PubMed/Corpus">001766</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001766</idno><idno type="wicri:Area/PubMed/Curation">001766</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001766</idno><idno type="wicri:Area/PubMed/Checkpoint">001534</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001534</idno><idno type="wicri:Area/Ncbi/Merge">000874</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Optimal Dosing and Dynamic Distribution of Vaccines in an Influenza Pandemic</title><author><name sortKey="Wood, James" sort="Wood, James" uniqKey="Wood J" first="James" last="Wood">James Wood</name></author><author><name sortKey="Mccaw, James" sort="Mccaw, James" uniqKey="Mccaw J" first="James" last="Mccaw">James Mccaw</name></author><author><name sortKey="Becker, Niels" sort="Becker, Niels" uniqKey="Becker N" first="Niels" last="Becker">Niels Becker</name></author><author><name sortKey="Nolan, Terry" sort="Nolan, Terry" uniqKey="Nolan T" first="Terry" last="Nolan">Terry Nolan</name></author><author><name sortKey="Macintyre, C Raina" sort="Macintyre, C Raina" uniqKey="Macintyre C" first="C. Raina" last="Macintyre">C. Raina Macintyre</name></author></analytic><series><title level="j">American Journal of Epidemiology</title><idno type="ISSN">0002-9262</idno><idno type="eISSN">1476-6256</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Disease Outbreaks (prevention & control)</term><term>Dose-Response Relationship, Immunologic</term><term>Humans</term><term>Immunization (statistics & numerical data)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Models, Statistical</term><term>Models, Theoretical</term><term>Time Factors</term><term>United States (epidemiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Facteurs temps</term><term>Flambées de maladies ()</term><term>Grippe humaine ()</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Immunisation ()</term><term>Modèles statistiques</term><term>Modèles théoriques</term><term>Relation dose-réponse (immunologie)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>États-Unis d'Amérique (épidémiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>United States</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Immunization</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term><term>États-Unis d'Amérique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Dose-Response Relationship, Immunologic</term><term>Humans</term><term>Models, Statistical</term><term>Models, Theoretical</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Facteurs temps</term><term>Flambées de maladies</term><term>Grippe humaine</term><term>Humains</term><term>Immunisation</term><term>Modèles statistiques</term><term>Modèles théoriques</term><term>Relation dose-réponse (immunologie)</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Limited production capacity and delays inherent in vaccine development are major hurdles to the widespread use of vaccines to mitigate the effects of a new influenza pandemic. Antigen-sparing vaccines have the most potential to increase population coverage but may be less efficacious. The authors explored this trade-off by applying simple models of influenza transmission and dose response to recent clinical trial data. In this paper, these data are used to illustrate an approach to comparing vaccines on the basis of antigen supply and inferred efficacy. The effects of delays in matched vaccine availability and seroconversion on epidemic size during pandemic phase 6 were also studied. The authors infer from trial data that population benefits stem from the use of low-antigen vaccines. Delayed availability of a matched vaccine could be partially alleviated by using a 1-dose vaccination program with increased coverage and reduced time to full protection. Although less immunogenic, an overall attack rate of up to 6% lower than a 2-dose program could be achieved. However, if prevalence at vaccination is above 1%, effectiveness is much reduced, emphasizing the need for other control measures.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><double pmid="19395691"><pmc><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Optimal Dosing and Dynamic Distribution of Vaccines in an Influenza Pandemic</title><author><name sortKey="Wood, James" sort="Wood, James" uniqKey="Wood J" first="James" last="Wood">James Wood</name></author><author><name sortKey="Mccaw, James" sort="Mccaw, James" uniqKey="Mccaw J" first="James" last="Mccaw">James Mccaw</name></author><author><name sortKey="Becker, Niels" sort="Becker, Niels" uniqKey="Becker N" first="Niels" last="Becker">Niels Becker</name></author><author><name sortKey="Nolan, Terry" sort="Nolan, Terry" uniqKey="Nolan T" first="Terry" last="Nolan">Terry Nolan</name></author><author><name sortKey="Macintyre, C Raina" sort="Macintyre, C Raina" uniqKey="Macintyre C" first="C. Raina" last="Macintyre">C. Raina Macintyre</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">19395691</idno><idno type="pmc">2691801</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2691801</idno><idno type="RBID">PMC:2691801</idno><idno type="doi">10.1093/aje/kwp072</idno><date when="2009">2009</date><idno type="wicri:Area/Pmc/Corpus">000572</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000572</idno><idno type="wicri:Area/Pmc/Curation">000572</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000572</idno><idno type="wicri:Area/Pmc/Checkpoint">000B77</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000B77</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Optimal Dosing and Dynamic Distribution of Vaccines in an Influenza Pandemic</title><author><name sortKey="Wood, James" sort="Wood, James" uniqKey="Wood J" first="James" last="Wood">James Wood</name></author><author><name sortKey="Mccaw, James" sort="Mccaw, James" uniqKey="Mccaw J" first="James" last="Mccaw">James Mccaw</name></author><author><name sortKey="Becker, Niels" sort="Becker, Niels" uniqKey="Becker N" first="Niels" last="Becker">Niels Becker</name></author><author><name sortKey="Nolan, Terry" sort="Nolan, Terry" uniqKey="Nolan T" first="Terry" last="Nolan">Terry Nolan</name></author><author><name sortKey="Macintyre, C Raina" sort="Macintyre, C Raina" uniqKey="Macintyre C" first="C. Raina" last="Macintyre">C. Raina Macintyre</name></author></analytic><series><title level="j">American Journal of Epidemiology</title><idno type="ISSN">0002-9262</idno><idno type="eISSN">1476-6256</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Limited production capacity and delays inherent in vaccine development are major hurdles to the widespread use of vaccines to mitigate the effects of a new influenza pandemic. Antigen-sparing vaccines have the most potential to increase population coverage but may be less efficacious. The authors explored this trade-off by applying simple models of influenza transmission and dose response to recent clinical trial data. In this paper, these data are used to illustrate an approach to comparing vaccines on the basis of antigen supply and inferred efficacy. The effects of delays in matched vaccine availability and seroconversion on epidemic size during pandemic phase 6 were also studied. The authors infer from trial data that population benefits stem from the use of low-antigen vaccines. Delayed availability of a matched vaccine could be partially alleviated by using a 1-dose vaccination program with increased coverage and reduced time to full protection. Although less immunogenic, an overall attack rate of up to 6% lower than a 2-dose program could be achieved. However, if prevalence at vaccination is above 1%, effectiveness is much reduced, emphasizing the need for other control measures.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI></pmc><pubmed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Optimal dosing and dynamic distribution of vaccines in an influenza pandemic.</title><author><name sortKey="Wood, James" sort="Wood, James" uniqKey="Wood J" first="James" last="Wood">James Wood</name><affiliation wicri:level="1"><nlm:affiliation>School of Public Health and Community Medicine, University of New South Wales, New South Wales, Australia. james.wood@unsw.edu.au</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>School of Public Health and Community Medicine, University of New South Wales, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Mccaw, James" sort="Mccaw, James" uniqKey="Mccaw J" first="James" last="Mccaw">James Mccaw</name></author><author><name sortKey="Becker, Niels" sort="Becker, Niels" uniqKey="Becker N" first="Niels" last="Becker">Niels Becker</name></author><author><name sortKey="Nolan, Terry" sort="Nolan, Terry" uniqKey="Nolan T" first="Terry" last="Nolan">Terry Nolan</name></author><author><name sortKey="Macintyre, C Raina" sort="Macintyre, C Raina" uniqKey="Macintyre C" first="C Raina" last="Macintyre">C Raina Macintyre</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19395691</idno><idno type="pmid">19395691</idno><idno type="doi">10.1093/aje/kwp072</idno><idno type="wicri:Area/PubMed/Corpus">001766</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001766</idno><idno type="wicri:Area/PubMed/Curation">001766</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001766</idno><idno type="wicri:Area/PubMed/Checkpoint">001534</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001534</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Optimal dosing and dynamic distribution of vaccines in an influenza pandemic.</title><author><name sortKey="Wood, James" sort="Wood, James" uniqKey="Wood J" first="James" last="Wood">James Wood</name><affiliation wicri:level="1"><nlm:affiliation>School of Public Health and Community Medicine, University of New South Wales, New South Wales, Australia. james.wood@unsw.edu.au</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>School of Public Health and Community Medicine, University of New South Wales, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Mccaw, James" sort="Mccaw, James" uniqKey="Mccaw J" first="James" last="Mccaw">James Mccaw</name></author><author><name sortKey="Becker, Niels" sort="Becker, Niels" uniqKey="Becker N" first="Niels" last="Becker">Niels Becker</name></author><author><name sortKey="Nolan, Terry" sort="Nolan, Terry" uniqKey="Nolan T" first="Terry" last="Nolan">Terry Nolan</name></author><author><name sortKey="Macintyre, C Raina" sort="Macintyre, C Raina" uniqKey="Macintyre C" first="C Raina" last="Macintyre">C Raina Macintyre</name></author></analytic><series><title level="j">American journal of epidemiology</title><idno type="eISSN">1476-6256</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Disease Outbreaks (prevention & control)</term><term>Dose-Response Relationship, Immunologic</term><term>Humans</term><term>Immunization (statistics & numerical data)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Models, Statistical</term><term>Models, Theoretical</term><term>Time Factors</term><term>United States (epidemiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Facteurs temps</term><term>Flambées de maladies ()</term><term>Grippe humaine ()</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Immunisation ()</term><term>Modèles statistiques</term><term>Modèles théoriques</term><term>Relation dose-réponse (immunologie)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>États-Unis d'Amérique (épidémiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>United States</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Immunization</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term><term>États-Unis d'Amérique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Dose-Response Relationship, Immunologic</term><term>Humans</term><term>Models, Statistical</term><term>Models, Theoretical</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Facteurs temps</term><term>Flambées de maladies</term><term>Grippe humaine</term><term>Humains</term><term>Immunisation</term><term>Modèles statistiques</term><term>Modèles théoriques</term><term>Relation dose-réponse (immunologie)</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Limited production capacity and delays inherent in vaccine development are major hurdles to the widespread use of vaccines to mitigate the effects of a new influenza pandemic. Antigen-sparing vaccines have the most potential to increase population coverage but may be less efficacious. The authors explored this trade-off by applying simple models of influenza transmission and dose response to recent clinical trial data. In this paper, these data are used to illustrate an approach to comparing vaccines on the basis of antigen supply and inferred efficacy. The effects of delays in matched vaccine availability and seroconversion on epidemic size during pandemic phase 6 were also studied. The authors infer from trial data that population benefits stem from the use of low-antigen vaccines. Delayed availability of a matched vaccine could be partially alleviated by using a 1-dose vaccination program with increased coverage and reduced time to full protection. Although less immunogenic, an overall attack rate of up to 6% lower than a 2-dose program could be achieved. However, if prevalence at vaccination is above 1%, effectiveness is much reduced, emphasizing the need for other control measures.</div></front></TEI></pubmed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000874 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000874 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= PMC:2691801
|texte= Optimal Dosing and Dynamic Distribution of Vaccines in an Influenza Pandemic
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:19395691" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |